FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Stenocare AS's Free Cash Flow for the
three
months ended in Mar. 2026 was kr0.09 Mil. Stenocare AS's Revenue for the
three
months ended in Mar. 2026 was kr3.00 Mil. Therefore, Stenocare AS's FCF Margin % for the quarter that ended in Mar. 2026 was 2.86%.
The historical rank and industry rank for Stenocare AS's FCF Margin % or its related term are showing as below:
OCSE:STENO'
s FCF Margin % Range Over the Past 10 Years
Min: -1054.86 Med: -271.87 Max: -41.66
Current: -41.66
During the past 8 years, the highest FCF Margin % of Stenocare AS was -41.66%. The lowest was -1054.86%. And the median was -271.87%.
OCSE:STENO's FCF Margin % is ranked worse than 87.94% of 962
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs OCSE:STENO: -41.66
Stenocare AS FCF Margin % Related Terms
Stenocare AS FCF Margin % Historical Data
* Premium members only.
The historical data trend for Stenocare AS's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:STENO vs ZTS, UTHR, VTRS: FCF Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Stenocare AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stenocare AS FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Stenocare AS's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Stenocare AS's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stenocare AS (OCSE:STENO) has a FCF Margin % of 2.86% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stenocare AS and its competitors. According to the industry distribution chart, Stenocare AS ranks #846 out of 962 companies in the Drug Manufacturers industry, placing it in the top 87.9%.
Is Stenocare AS's FCF Margin % too high?
Stenocare AS's current FCF Margin % is 2.86%. The Drug Manufacturers industry median FCF Margin % is 2.51. Stenocare AS's value of 2.86% is 13.9% above this industry median. Based on the distribution chart, Stenocare AS ranks #846 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Stenocare AS has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Stenocare AS's FCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Stenocare AS ranks #846 out of 962 companies for FCF Margin %. This places Stenocare AS in the lower half of its industry. The industry median FCF Margin % is 2.51. Stenocare AS's value of 2.86% is 13.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Stenocare AS's current FCF Margin % of 2.86% is 13.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Stenocare AS and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stenocare AS's current FCF Margin % is 2.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stenocare AS stock overvalued right now?
Based on GuruFocus' analysis, Stenocare AS (OCSE:STENO) is currently considered Possible Value Trap. The stock's GF Value™ is kr2.31, compared to a current price of kr1.00 — trading 56.7% below its estimated fair value. The current FCF Margin % is 2.86% and 13.9% above the Drug Manufacturers industry median of 2.51. Stenocare AS's overall GF Score™ is 49/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Stenocare AS (OCSE:STENO), the current FCF Margin % is 2.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stenocare AS (OCSE:STENO) Overvalued in 2026?
Based on GuruFocus' analysis, Stenocare AS stock appears to be undervalued.
The current stock price of kr1.00 is trading 56.7% below its estimated GF Value™ of kr2.31.
GuruFocus considers Stenocare AS to be Possible Value Trap.
Key valuation signals for OCSE:STENO:
FCF Margin %: 2.86%
GF Value™: kr2.31 vs. price of kr1.00 (56.7% below fair value)
Industry Position: 13.9% above the Drug Manufacturers median (#846 of 962)
No single metric tells the full story. See the OCSE:STENO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The company's business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway.
49GF Score
Get the complete analysis for OCSE:STENO
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:STENO has been successfully added to your 
